Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.34 |
| ▸ | HTR2B | P41595 | 5/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24252075 | 0.83 | HTR2A (0.33) | HTR2CHTR2BHTR2AFFAR1CES2 | |
| SCHEMBL7714249 | 0.81 | KCNH2 (0.31) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL16421053 | 0.81 | KCNH2 (0.31) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL13019837 | 0.80 | SLC6A2 (0.43) | KCNH2TMEM97SIGMAR1FFAR1CES2 | |
| SCHEMBL22279635 | 0.78 | KCNH2 (0.37) | KCNH2TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL7632894 | 0.78 | — | — | |
| SCHEMBL17186941 | 0.78 | ELANE (0.33) | HTR2CHTR2BHTR2A | |
| SCHEMBL28211919 | 0.77 | KCNH2 (0.30) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL7711832 | 0.77 | HTR2C (0.32) | HTR2CHTR2B | |
| SCHEMBL17186806 | 0.77 | PPARA (0.47) | CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101891599-B | 3,4,5-trifluoro-phynyl tertiary butyl ether | GENCHEM CHANGZHOU CO LTD | 2013-04-10 | — | — | CN | claimed |
| CN-101891599-A | 3,4,5-trifluoro-phynyl tertiary butyl ether | GENCHEM CHANGZHOU CO LTD | 2010-11-24 | — | — | CN | claimed |
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | MAPK11, WEE1, NOS1 | HTR2C 3134/4885HTR2B 3455/4885HTR2A 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.